Gritstone bio Inc

NASDAQ:GRTSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Contact Information

Headquarters

5959 HORTON STREET, SUITE 300EMERYVILLE, CA, United States 94608

Phone

510-871-6100

Fax

510-597-1488

Executives

Independent Chairman of the Board

Elaine Jones

President, Chief Executive Officer, Director

Andrew Allen

Chief Financial Officer, Executive Vice President

Vassiliki Economides

Chief Operating Officer, Executive Vice President

Erin Jones

Executive Vice President, Chief Business Officer

Matthew Hawryluk